Memigmin (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx that can cause neuronal damage. By moderating glutamate‑mediated excitotoxicity, it helps preserve neuronal function in patients with Alzheimer’s disease.

The dose of Memigmin is individualized by the prescribing clinician. Typically, treatment starts with a low dose that is gradually increased based on tolerability and clinical response, following established prescribing guidelines.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Memigmin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While those agents increase acetylcholine levels, memantine modulates glutamatergic activity. Both classes may be used together, but memantine is generally reserved for moderate‑to‑severe stages where excitotoxicity plays a larger role.

Memigmin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Memigmin is taken orally as a tablet. Patients should swallow the tablet whole with water, and it may be taken with or without food. Consistency in administration time each day helps maintain stable drug levels.

The most serious adverse events include the occurrence of seizures, severe skin reactions such as Stevens‑Johnson syndrome, and neuropsychiatric symptoms like hallucinations or profound confusion. Any of these signs require immediate medical evaluation.

Memigmin is contraindicated in individuals with known hypersensitivity to memantine or any tablet excipients. Patients with severe renal impairment should avoid use, and those with a history of uncontrolled seizures should be evaluated carefully before initiating therapy.